Posted by Michael Wonder on 28 Sep 2023
Akebia announces approval of Vafseo (vadadustat) in Australia
26 September 2023 - Akebia Therapeutics today announced that Australia's TGA has granted approval for Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis.
